Heron gains on positive pain med combo data

Heron Therapeutics (HRTX +2.6%) is up on average volume in response to its announcement of positive results from pain management study evaluating the combination of HTX-011 and over-the-counter pain meds (acetaminophen and ibuprofen) for managing postoperative pain.

90% of patients receiving the combo regimen did not need opioids for postoperative pain through 72 hours after surgery, superior to 51%, 40% and 22% of patients receiving HTX-011, bupivacaine and placebo, respectively.

81% of patients receiving the combo remained opioid-free through 28 days after surgery.

The company’s U.S. marketing application seeking approval for HTX-011 + meloxicam is currently under FDA review with an action date of April 30.

https://seekingalpha.com/news/3420463-heron-3-percent-positive-htxminus-011-data